Hyalex Earns FDA IDE for Pivotal Trial of Freestyle Knee Implant

Hyalex Orthopedics has earned U.S. Food and Drug Administration (FDA) approval for a supplemental Investigational Device Exemption (IDE) for its Freestyle knee implant. The approval allows the company to expand its early feasibility study into a pivotal clinical trial of its novel knee implant.

The Freestyle knee implant was engineered for patients suffering from cartilage damage and early osteoarthritis of the femoral condyle(s) to regain an active lifestyle.

The planned trial will take place at leading orthopedic centers in the U.S. and Europe. It will assess the device’s safety and effectiveness in restoring mobility and improving outcomes. Investigators plan to enroll a diverse population of patients that currently have limited options for treatment.

The trial will also build on favorable clinical results that surgeons involved in Freestyle’s early feasibility study have seen. This includes the study’s national principal investigator, Sabrina Strickland, MD of Hospital for Special Surgery.

“In our early clinical evaluations, the HYALEX Freestyle Knee Implant demonstrated exceptional promise in mimicking natural joint mechanics and helping patient’s return to their active lifestyle,” said Dr. Strickland. “The ability to help these patients, who have limited options today, could significantly impact the future treatment of chondral and osteochondral defects in the knee.”

“This FDA approval validates the rigorous research and development behind our Freestyle Knee Implant and propels us into the next phase of clinical evaluation,” said Carl Vause, CEO of Hyalex. “We are committed to advancing orthopedic care by delivering innovative solutions that address the unmet needs of cartilage gap patients, which is estimated to represent a $2 billion market in the US alone.”